Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2023-185875

Published: 2023

Journal Articles

An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages

Blood (2021) 138 (Supplement 1): 2805.

https://doi.org/10.1182/blood-2021-148336

Published: 2021

Journal Articles

Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

Veit Buecklein, MD, Viktoria Blumenberg, MD, Josephine Ackermann, Christian Schmidt, MD, Kai Rejeski, MD, Niklas Mueller, MD, Anna Reischer, MD, Louisa von Baumgarten, MD, Florian Schoeberl, MD, Andreas Humpe, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-142932

Published: 2020

Journal Articles

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Judith Petersen, Thies Rösner, PhD, Max Kölling, Katja Klausz, PhD, Christian Kellner, PhD, Andreas Humpe, MD, George J Weiner, MD, Denis Martin Schewe, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2019) 134 (Supplement_1): 5305.

https://doi.org/10.1182/blood-2019-122940

Published: 2019

Journal Articles

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Anna Sophie Hartjen, Andreas Krumbholz, MD, Florian Thieme, PhD, Natalie Schub, MD, Andreas Humpe, MD, Michaela Kotrova, Monika Brüggemann, MD, Martin Gramatzki, MD, Andreas Guenther, MD

Blood (2017) 130 (Supplement 1): 5490.

https://doi.org/10.1182/blood.V130.Suppl_1.5490.5490

Published: 2017

Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 1779.

https://doi.org/10.1182/blood.V124.21.1779.1779

Published: 2014

Journal Articles

Targeting CD96 For Antibody Based Elimination Of Leukemic Stem Cells In AML: A New Strategy In Stem Cell Transplantation

Matthias Staudinger, PhD, Christian Kellner, PhD, Matthias Peipp, PhD, Natalie Schub, MD, Andreas Humpe, MD, Martin Gramatzki, MD

Blood (2013) 122 (21): 3972.

https://doi.org/10.1182/blood.V122.21.3972.3972

Published: 2013

Journal Articles

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Stefanie Derer, PhD, Pia Glorius, PhD, Martin Schlaeth, Stefan Lohse, PhD, Umesh Muchhal, Ph.D., John Desjarlais, Andreas Humpe, MD, Thomas Valerius, MD, Matthias Peipp, PhD

Blood (2013) 122 (21): 3466.

https://doi.org/10.1182/blood.V122.21.3466.3466

Published: 2013

Journal Articles

The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Christian Kellner, Eugene A Zhukovsky, Monika Brüggemann, Michael Kneba, MD, PhD, André Schrauder, Martin Schrappe, Roland Repp, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2012) 120 (21): 1502.

https://doi.org/10.1182/blood.V120.21.1502.1502

Published: 2012

Journal Articles

Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity

Christian Kellner, Tina Maurer, Daniela Hallack, Roland Repp, Jan G.J. van de Winkel, Paul W.H.I. Parren, PhD, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2011) 118 (21): 103.

https://doi.org/10.1182/blood.V118.21.103.103

Published: 2011

Journal Articles

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

Christian Kellner, Daniela Hallack, Pia Glorius, Matthias Staudinger, Sahar Mohseni Nodehi, Tina Maurer, Roland Repp, Michel de Weers, Jan G.J. van De Winkel, Paul W.H.I. Parren, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2843.

https://doi.org/10.1182/blood.V116.21.2843.2843

Published: 2010

Journal Articles

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

Pia Glorius, Anne Baerenwaldt, Christian Kellner, Matthias Staudinger, Paul W.H.I. Parren, Jan G. J. van De Winkel, Andreas Humpe, Thomas Valerius, Roland Repp, Falk Nimmerjahn, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2846.

https://doi.org/10.1182/blood.V116.21.2846.2846

Published: 2010

Journal Articles

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Blood (2010) 116 (14): 2438–2447.

https://doi.org/10.1182/blood-2010-03-275420

Published: 2010

Includes: Supplemental data

Journal Articles

Development and Evaluation of a Novel Flow Cytometric Assay for Determination of Fcγ Receptor IIIa-158 V/F Dimorphism.

Sebastian Boettcher, MD, Matthias Ritgen, MD, Christiane Pott, MD, Andreas Humpe, MD, Michael Kneba, MD, PhD

Blood (2004) 104 (11): 1366.

https://doi.org/10.1182/blood.V104.11.1366.1366

Published: 2004

Journal Articles

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR

Matthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, Andreas Humpe, Monika Brüggemann, Christiane Pott, Thorsten Raff, Alexander Kröber, Donald Bunjes, Richard Schlenk, Norbert Schmitz, Hartmut Döhner, Michael Kneba, Peter Dreger

Blood (2004) 104 (8): 2600–2602.

https://doi.org/10.1182/blood-2003-12-4321

Published: 2004

NARROW

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages

Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Targeting CD96 For Antibody Based Elimination Of Leukemic Stem Cells In AML: A New Strategy In Stem Cell Transplantation

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Development and Evaluation of a Novel Flow Cytometric Assay for Determination of Fcγ Receptor IIIa-158 V/F Dimorphism.

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only